You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Drugs in ATC Class J01GB


✉ Email this page to a colleague

« Back to Dashboard


Drugs in ATC Class: J01GB - Other aminoglycosides

J01GB Market Analysis and Financial Projection

Last updated: March 23, 2025

The ATC class J01GB (Other aminoglycosides) encompasses antibiotics like gentamicin, tobramycin, amikacin, and neomycin, which are critical for treating serious bacterial infections. Below is an analysis of their market dynamics and patent landscape:


Market Dynamics

Growth Trends

  • Current Valuation: Estimated at $1.8–2.02 billion in 2024, with projections to reach $2.46–2.67 billion by 2029–2030, reflecting a CAGR of 4.8–6.3% [8][12][17].
  • Key Drivers:
    • Rising bacterial infections (e.g., respiratory diseases, sepsis) and veterinary use [2][8].
    • Innovations in drug delivery (e.g., inhaled formulations like tobramycin and amikacin for lung infections) [4][6].
    • Government initiatives subsidizing antibiotics in low-resource regions [2][8].

Segment Insights

  • Dominant Products: Gentamicin leads with 32.5% market share, favored for its efficacy against Gram-negative bacteria [8].
  • Administration Routes: Parenteral (injectable) forms hold 30.8% share due to rapid action in critical care [8].
  • Regional Markets:
    • Asia-Pacific (41.5% share): Driven by population growth and healthcare investments [8][16].
    • Europe: Second-largest market, supported by policies promoting antibiotic stewardship [16].

Challenges

  • Safety Concerns: Nephrotoxicity and ototoxicity limit prolonged use [8][16].
  • Antimicrobial Resistance: While aminoglycosides remain effective against many resistant strains, resistance mechanisms are evolving [2].

Patent Landscape

Key Patents and Expirations

  • Aminoglycoside Analogs: Patents like US-9688711-B2 (expiring 2028–2031) and US-9266919-B2 cover novel compounds and formulations [3][5][14].
  • Zemdri (Plazomicin): Protected by patents until 2028–2031, with exclusivities expiring in 2028 [5].
  • Inhaled Formulations: Patents for aerosolized tobramycin (e.g., US8715623) emphasize targeted delivery for respiratory infections [11].

Impact of Patent Expiries

  • Post-2028, generic competition will intensify, particularly in Asia-Pacific, where large-scale generic manufacturing is already prominent [16].
  • Innovations in combination therapies (e.g., aminoglycosides + β-lactams) and personalized dosing may offset generic pressure [12][16].

Competitive and Regulatory Outlook

  • Major Players: Mix of originators (e.g., Novartis, Cipla) and generics manufacturers [5][13][16].
  • Strategic Trends:
    • Biotechnological Advancements: Protein synthesis inhibitors and modified analogs to combat resistance [2][12].
    • Antibiotic Stewardship: Emphasis on optimizing use to prolong efficacy [7][12].

Key Takeaways

  • Market Growth: Sustained by infectious disease burden and formulation innovations.
  • Patent Cliffs: Post-2028 expiries will reshape the competitive landscape, favoring generics.
  • Future Opportunities: Inhalation therapies and combination regimens address unmet needs in critical care and resistant infections.
“The expiry of patent exclusivity has led to large-scale generic manufacturing of aminoglycosides, particularly in Asia-Pacific.” – Globenewswire [16]

References

  1. https://www.mdpi.com/2079-6382/12/1/126
  2. https://www.gminsights.com/industry-analysis/aminoglycosides-market
  3. https://pubchem.ncbi.nlm.nih.gov/patent/US-9688711-B2
  4. https://atcddd.fhi.no/atc_ddd_index/?code=J01GB
  5. https://pharsight.greyb.com/drug/zemdri-patent-expiration
  6. https://atcddd.fhi.no/atc_ddd_index/?code=J01GB&showdescription=no
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10042087/
  8. https://market.us/report/aminoglycosides-market/
  9. https://pubchem.ncbi.nlm.nih.gov/compound/441305
  10. https://www.mdpi.com/2079-6382/12/7/1109
  11. https://www.drugpatentwatch.com/p/patent/8715623
  12. https://www.researchandmarkets.com/reports/5785580/aminoglycosides-market-report
  13. https://www.drugpatentwatch.com/p/generic/gentamicin+sulfate
  14. https://pubchem.ncbi.nlm.nih.gov/patent/US9266919
  15. https://www.mdpi.com/1660-4601/16/18/3376
  16. http://www.globenewswire.com/news-release/2019/07/12/1882033/0/en/Worldwide-Aminoglycosides-Markets-2019-to-2024-Expiry-of-Patent-Exclusivity-has-Led-to-Large-Scale-Generic-Manufacturing-of-Aminoglycosides-Particularly-in-the-Developing-Region-of.html?culture=en-us
  17. https://www.360iresearch.com/library/intelligence/aminoglycosides

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.